All market share wars are, to one degree or another, fought on multiple fronts. While companies pursue aggressively a forward strike to convince customers to buy more products, they also, when appropriate, engage in a rear-guard action to keep other competitors from entering the market. Nowhere is this truer than in markets like interventional cardiology, where even small differences in design features can have a huge impact on product performance and thus are often crucial to customer adoption. The latest such rear-guard action: the lawsuit filed this past February in The Netherlands by Boston Scientific Corp. to keep Conor Medsystems Inc. from selling its paclitaxel-coated stent in Europe.
The suit itself was hardly a surprise. Boston Scientific officials had been saying publicly for several months that they felt that Conor's paclitaxel-coated stent was in violation of its IP...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?